Spyre Therapeutics, Inc.SYRENASDAQ

Revenue (LTM)

Net Income (LTM)

$-155M

+25.4% YoY

Free Cash Flow

$-169M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	19	2↓87.6%	1↓62.0%	0	0
Gross Profit	19	2↓87.6%	1↓62.0%	0	-172
Operating Income	-66	-85↓29.1%	-242↓185.8%	-209↑13.9%	-210↓0.5%
Net Income	-66	-84↓27.4%	-339↓304.2%	-208↑38.6%	-155↑25.4%
EBITDA	-64	-83↓29.3%	-128↓54.1%	-208↓63.0%	-210↓0.8%
EPS Diluted	-25.02	-24.86↑0.6%	-46.15↓85.6%	-3.18↑93.1%	-1.98↑37.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	15	35↑130.2%	189↑441.8%	89↓52.7%	86↓4.1%
Total Current Assets	99	62↓37.0%	342↑448.6%	608↑78.2%	778↑27.8%
Total Assets	110	71↓35.3%	342↑380.5%	608↑78.0%	778↑27.8%
Total Current Liabilities	20	15↓27.2%	32↑118.2%	54↑69.1%	59↑8.6%
Total Liabilities	26	21↓19.8%	158↑657.4%	91↓42.6%	63↓31.0%
Total Equity	84	50↓40.1%	184↑265.8%	518↑181.4%	715↑38.1%
Total Debt	5	5↓8.5%	0	0	0
Net Debt	-10	-30↓199.9%	-189↓524.8%	-89↑52.7%	-86↑4.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-54	-80↓49.2%	-100↓24.7%	-157↓57.6%	-169↓7.5%
Capital Expenditure	-1	-0↑93.4%	0	0	0
Free Cash Flow	-54	-80↓47.7%	-100↓24.6%	-157↓57.6%	-169↓7.5%
Stock-Based Comp	8	7↓11.5%	26↑261.1%	45↑74.6%	38↓16.1%
Net Change in Cash	-75	19↑125.9%	153↑686.2%	-100↓165.3%	-4↑96.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance